


Figure 1: Time concentration curve for example 125 and released riluzole via both intravenous and oral administration.



5

Figure 2: Melanoma (C8161) xenograft study in nude mice with example 125 and riluzole given orally (RIL = Riluzole).





Figure 3: Time-concentration curves for 2-Amino-N-[[methyl({[6-(trifluoromethoxy)-1,3-benzo thiazol-2-yl]carbamoyl)methyl]carbamoyl)methyl]acetamide (Example 204) and released riluzole via both intravenous and oral administration.



5

Figure 4: Melanoma (C8161) xenograft study in nude mice with example 204 and riluzole given orally (RIL = Riluzole).





Figure 5: PK in fasted male mice for Example 204 , IV administration, 1 mg/kg. and PO administration 5 mg/kg. Monitor disappearance of Prodrug and appearance of riluzole.

Mouse PK curves

IV 1 mg/kg



PO 5 mg/kg





Figure 6: PK in Cynomolgus Monkey for Example 204 , IV administration, 1 mg/kg. and PO administration 5 mg/kg. Monitor appearance of riluzole.

Cynomolgus Monkeys PK

IV 1mg/kg



PO 3mg/kg

